Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Qaseem A, Forciea MA, McLean RM, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: A clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166:818-39. [PMID: 28492856] doi:10.7326/M15-1361
Kanis JA, Cooper C, Rizzoli R, Abrahamsen B, Al-Daghri NM, Brandi ML, et al; European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int. 2017;28:2023-34. [PMID: 28451733] doi:10.1007/s00198-017-4009-0
Yang XC, Deng ZH, Wen T, Luo W, Xiao WF, Zhao RB, et al. Network metaanalysis of pharmacological agents for osteoporosis treatment and fracture prevention. Cell Physiol Biochem. 2016;40:781-95. [PMID: 27915335]
Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al; ACTIVE Study Investigators. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial. JAMA. 2016;316:722-33. [PMID: 27533157] doi:10.1001/jama.2016.11136
Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, et al. Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: Results of the ACTIVExtend trial. Mayo Clin Proc. 2017;92:200-210. [PMID: 28160873] doi:10.1016/j.mayocp.2016.10.009
